Novo Nordisk has announced the company will no longer be working with Hims & Hers Health, Inc., and that direct access to Wegovy will no longer be available to Hims & Hers Health, Inc. via NovoCare Pharmacy.
In late April, the FDA resolved the Wegovy shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy through NovoCare Pharmacy, Novo Nordisk began collaborating with telehealth companies. However, over a month into the collaboration, concerns have surfaced around Hims & Hers Health, Inc.’s practices, including the mass distribution of compounded drugs and promotional claims that are allegedly misleading—raising questions about regulatory compliance and patient safety. "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," said Dave Moore, executive vice president, U.S. Operations of Novo Nordisk Inc. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety—and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action."
More information can be found on semaglutide.com.